Innovent's IBI363 Shows Striking Efficacy in Hard-to-Treat Lung Cancer

SUZHOU, China – May 23, 2026 – New data on an experimental cancer drug has ignited hope for a notoriously difficult-to-treat patient population, potentially expanding the reach of immunotherapy to thousands diagnosed with advanced lung cancer each year. Innovent Biologics, in partnership with Takeda, announced preliminary results for its first-in-class drug, IBI363, showing remarkably high response rates in patients whose tumors typically don't respond well to current immune-based therapies.

The findings, presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, stem from a proof-of-concept study evaluating IBI363 combined with chemotherapy as a first-line treatment for advanced non-small cell lung cancer (NSCLC). The data has drawn significant attention for its potential to address a major unmet need in oncology.

A New Weapon for 'Cold' Tumors

At the heart of the excitement is IBI363's performance in patients with low or negative levels of a protein biomarker called PD-L1. For years, PD-L1 levels have helped doctors predict which patients are most likely to benefit from blockbuster immunotherapy drugs known as PD-1/PD-L1 inhibitors. Tumors with high PD-L1 levels are considered "hot" and are often susceptible to these treatments, which work by taking the brakes off the immune system.

However, a large portion of NSCLC patients have tumors with low or no PD-L1 expression—so-called "cold" tumors. These cancers are adept at hiding from the immune system, and current immunotherapies offer them limited benefit. This is the challenge Innovent's IBI363 was designed to overcome.

IBI363 is a bispecific fusion protein, meaning it has two distinct functions in one molecule. One part acts like a conventional PD-1 inhibitor, blocking the pathway that cancer cells use to evade immune attack. The second, more innovative part, is a modified version of Interleukin-2 (IL-2), a powerful immune-signaling protein. While older IL-2 therapies were often limited by severe toxicity, IBI363's IL-2 component is "alpha-biased," engineered to selectively activate the most potent cancer-fighting T-cells within the tumor while minimizing widespread, toxic side effects. This dual mechanism essentially provides a one-two punch: it unmasks the tumor with the PD-1 blocker and then delivers a targeted, powerful boost to the immune cells best equipped to destroy it.

"IBI363 is designed to break through the bottleneck of current immunotherapy," said Dr. Hui Zhou, Chief R&D Officer (Oncology Pipeline) of Innovent, in a statement. "Data from this study demonstrate that by designing a dosing strategy consistent with its immune mechanism, IBI363 achieved an encouraging response rate, leveraging its strong advantages in effectively activating the IL-2 pathway in first-line NSCLC patients with PD-L1 negative or low expression."

By the Numbers: Benchmarking the Breakthrough

The preliminary data from the Phase 1 study in China is compelling, particularly from one specific dosing regimen. In a group of 22 patients with PD-L1 negative or low-expressing tumors, a strategy involving an initial higher dose followed by a lower maintenance dose (the 3→1.5 mg/kg regimen) achieved an objective response rate (ORR) of 86.4%, meaning tumors shrank significantly in nearly nine out of ten patients. Even more impressively, the disease control rate (DCR) was 100%, indicating that every patient in this group saw their cancer either shrink or stabilize.

These figures stand in stark contrast to the current standards of care. In the pivotal KEYNOTE-189 and KEYNOTE-407 trials, which established pembrolizumab (Keytruda) plus chemotherapy as a frontline treatment, the ORRs for patients with low or negative PD-L1 expression ranged from approximately 33% to 67%. While direct cross-trial comparisons are fraught with caveats, the magnitude of the difference suggests IBI363 could represent a significant leap forward for this patient population.

The efficacy was also consistent across different types of NSCLC, including squamous and non-squamous histologies. Furthermore, the 3→1.5 mg/kg regimen demonstrated a more favorable safety profile than other doses tested, with a lower rate of severe treatment-related side effects. This balance of potent efficacy and manageable safety is crucial for any new cancer therapy and supports this dosing strategy as the one to carry forward into larger, more definitive trials.

Innovent's Global Ambition and the Takeda Partnership

The promising results for IBI363 are not just a scientific victory but also a significant strategic milestone for Innovent Biologics. Founded in 2011, the Suzhou-based company has rapidly emerged as a major force, moving beyond China's borders to compete on the global biopharmaceutical stage.

A critical component of this global strategy is its collaboration with Japanese pharmaceutical giant Takeda. Under their agreement, the two companies are co-developing IBI363 (known by Takeda's code, TAK-928) globally. The partnership leverages Innovent's discovery and early development engine with Takeda's extensive global clinical trial and commercialization infrastructure. This allows a promising asset discovered in China to be developed for patients worldwide, validating Innovent's research capabilities and accelerating its path to major markets like the United States.

This model of East-West collaboration is becoming increasingly important in an industry where the cost and complexity of drug development are immense. For Innovent, it provides a powerful partner to challenge established oncology players. For Takeda, it adds a first-in-class asset with blockbuster potential to its oncology pipeline, addressing a clear area of high unmet need.

The Road Ahead: From Promising Data to Clinical Practice

While the early data is highly encouraging, IBI363 still has a long road to travel before it becomes a standard treatment. The next and most critical step is already underway: a randomized, head-to-head clinical trial. This study will directly compare IBI363 plus chemotherapy against the current gold standard, pembrolizumab plus chemotherapy, in first-line advanced NSCLC patients across all PD-L1 expression levels. The results of this trial will be pivotal in determining the drug's ultimate place in the treatment landscape.

In the meantime, Innovent and Takeda are pursuing a broad development program for IBI363, reflecting their confidence in its unique mechanism. The drug is being tested in other difficult-to-treat cancers, including immunotherapy-resistant squamous NSCLC, advanced melanoma, and colorectal cancer. Its potential is further underscored by multiple expedited regulatory designations, including two Fast Track Designations from the U.S. Food and Drug Administration (FDA) and three Breakthrough Therapy Designations from China's National Medical Products Administration (NMPA). These designations are reserved for drugs that may demonstrate substantial improvement over available therapies and are intended to speed up the development and review process, signaling a clear recognition of IBI363's potential from global health authorities.